Oral anti-VEGF, anti-PDGF advanced in pipeline of wet AMD treatments

LAS VEGAS — Early data from study of orally administered X-82 show promise for treating wet age-related macular degeneration, according to a presentation here. X-82 (Tyrogenex) is a tyrosine kinase inhibitor (TKI) with both anti-VEGF and anti- platelet-derived growth factor (PDGF) activities.